|
A case report on Deflazacort Induced Stevens Johnson Syndrome/Toxic Epidermal Necrolysis Overlap
|
|
| Author:
|
VADDE VINUSHA, DIVYA REDDY GADWALA, JUMANA HAKIM, ABHISHEK TIWARI, DR. RAMYA BALAPRABHA, VARSHA K.L.
|
| Abstract:
|
Deflazacort (DFZ) is an adrenal Glucocorticoid. DFZ is a prodrug of the corticosteroid active metabolite 21-des DFZ, which has anti-inflammatory and immunosuppressive effects via action on the glucocorticoid receptor. Deflazacort has been widely used instead of prednisone and prednisolone for managing nephrotic syndrome because of its equivalent anti-inflammatory efficacy to prednisolone. SJS-TEN is a potentially life-threatening dermatologic disorder and a severe cutaneous ADR that involves skin and mucous membrane. characterized by widespread erythema, necrosis and bullous detachment, resulting in exfoliation and possible sepsis and/or death. Which is most commonly drug induced, SJS-TEN is characterized by inappropriate immune activation in response to certain medications or their metabolites. The exact pathogenic mechanism of SJS-TEN is still uncertain. The exposure of drugs has increased with demographic shifts associated with a higher morbidity of the population. Along with this phenomenon, a rise in the incidence of the adverse drug reactions (ADRs) has been observed. Although steroids are used for the treating SJS-TEN. It is essential to understand its potential adverse effects. This rare case report addresses the fact that severe hypersensitivity reactions can occur with Deflazacort, which can be potentially dangerous and life threatening, this case report also adds a note on the diagnosis and management of SJS-TEN.
|
| Keyword:
|
Stevens Johnson Syndrome [SJS], Toxic Epidermal Necrolysis [TEN], Deflazacort [DFZ].
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.394
|
| Download:
|
Request For Article
|
|
|